Client News

InflaRx to Present at Upcoming Scientific and Investor Conferences

InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine

AiCuris nominates team of researchers from the Universitätsklinikum Erlangen as one of the 2022 winners of AiCubator Resident Status, a corporate innovation accelerator initiative

Destiny Pharma: Interim results for the six months ended 30 June 2022

iOmx Therapeutics appoints Professor Frances Balkwill to the Scientific Advisory Board

Destiny Pharma announces positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans

ABIVAX PHASE 2B STUDY RESULTS OF OBEFAZIMOD (ABX464) IN ULCERATIVE COLITIS PUBLISHED IN THE LANCET GASTROENTEROLOGY & HEPATOLOGY

Spexis provides business update and announces financial results for the first half of 2022

ABIVAX PUBLISHES A PROSPECTUS IN THE CONTEXT OF ITS CAPITAL INCREASE

ABIVAX ANNOUNCES SUCCESSFUL OVERSUBSCRIBED EUR 49.2M CROSS-OVER FINANCING WITH TOP-TIER US AND EUROPEAN BIOTECH INVESTORS